2025年6月30日,泰德医药(浙江)股份有限公司(以下简称:泰德医药)正式在港交所挂牌上市。此次上市全球发售1680万股H股,占发行后总股本的11.85%,每股定价30.60港元,公开发售获301.15倍认购。截至首日收盘,泰德医药股价30.8港元,市值为 44 亿港元。泰德医药是一家位于杭州钱塘的生物医药企业,提供从早期发现、临床前研究、临床开发以及商业化生产的全周期服务,主要包括多肽NCE...
Source Link2025年6月30日,泰德医药(浙江)股份有限公司(以下简称:泰德医药)正式在港交所挂牌上市。此次上市全球发售1680万股H股,占发行后总股本的11.85%,每股定价30.60港元,公开发售获301.15倍认购。截至首日收盘,泰德医药股价30.8港元,市值为 44 亿港元。泰德医药是一家位于杭州钱塘的生物医药企业,提供从早期发现、临床前研究、临床开发以及商业化生产的全周期服务,主要包括多肽NCE...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.